Using ultrasound to treat obstructive hypertrophic cardiomyopathy
Official title: Minimally Invasive High Intensity Therapeutic Ultrasound for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Funded at Coridea, LLC · NIH-10834827 · Data updated 2026-11-12
This study is testing a new, less invasive ultrasound treatment for people with obstructive hypertrophic cardiomyopathy (oHCM) to help reduce heart blockage safely, especially for those who can't have traditional surgery.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coridea, LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $941,991 |
| NIH project number | 5R44HL167428-02 |
| Project ID | NIH-10834827 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with obstructive hypertrophic cardiomyopathy who have not responded to medical management and are at risk of severe complications.
✕Less likely to help
Patients with non-obstructive forms of hypertrophic cardiomyopathy or those who are not candidates for septal reduction therapy may not benefit from this research.
What this research studies
This research investigates a new treatment for obstructive hypertrophic cardiomyopathy (oHCM) using high-intensity therapeutic ultrasound. The approach involves a minimally invasive procedure that targets the heart's interventricular septum to reduce obstruction without the risks associated with traditional surgical methods. By utilizing a catheter inserted through the femoral vein, the treatment aims to ablate the problematic heart tissue while preserving the heart's electrical conduction system. This method could provide a safer alternative for patients who are not candidates for existing surgical options.
Why it matters
Potential benefit: If successful, this research could significantly improve the quality of life and survival rates for patients with obstructive hypertrophic cardiomyopathy.
How similar studies have gone: While traditional surgical approaches have been successful, this novel ultrasound technique represents a new and untested method in the treatment of obstructive hypertrophic cardiomyopathy.
Where this research is happening
-
Coridea, LLC
New York, United States Active
Researchers
- Principal investigator: Levin, Howard — Coridea, LLC
- Study coordinator: Levin, Howard
Related research
Other NIH-funded projects on the same topics.
-
High-Intensity Ultrasound to Shrink the Septum in Hypertrophic Cardiomyopathy
A new, less invasive ultrasound-based treatment is being developed to reduce the thickened heart septum in people with obstructive hypertrophic cardiomyopathy.
-
Using ultrasound to treat obstructive hypertrophic cardiomyopathy
This study is testing a new, less invasive treatment for people with obstructive hypertrophic cardiomyopathy (oHCM) that uses ultrasound to help reduce heart muscle blockage, making it a safer option than traditional surgery.
-
Using high-intensity ultrasound to treat heart obstruction in hypertrophic cardiomyopathy
This study is testing a new, less invasive ultrasound treatment for people with obstructive hypertrophic cardiomyopathy (HCM) to help reduce heart muscle thickness and improve heart function.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.